<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745966</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-NKR-SER-2008/1</org_study_id>
    <nct_id>NCT00745966</nct_id>
  </id_info>
  <brief_title>Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder</brief_title>
  <acronym>POLE</acronym>
  <official_title>A 8-Week, Multicenter, Open-Label, Observational Study of Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to reassure the clinical study data on atypical antipsychotics
      effect on quality of life in Korean Bipolar patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>The change from the baseline to week 8 in Short Form of the Quality of Life Enjoyment and satisfaction Questionnaire (Q-LES-Q) score</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from the baseline to week 8 in CGI-BP and GAF scale score.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Naturalistic</condition>
  <condition>Observational</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient and the patient's legal representative (if any) must understand the nature
             of the study and must have given written consent.

          -  Meet DSM-IV-TR criteria for bipolar disorder (bipolar I disorder, bipolar II disorder)
             at the time of baseline.

        Exclusion Criteria:

          -  Serious or unstable, medical illness. Subjects with chronic illness may be included
             but must be stable and otherwise physically healthy on the basis of a physical
             examination, medical history.

          -  Known intolerance for or lack of response to atypical antipsychotics , as judged by
             the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joon-Woo Bahn</last_name>
    <role>Study Director</role>
    <affiliation>Astrazeneca, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyunggi-do</city>
        <state>Choonchun-si</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RFesearch Site</name>
      <address>
        <city>Dae-gu</city>
        <state>Joong-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>October 3, 2008</last_update_submitted>
  <last_update_submitted_qc>October 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>Joon-Woo Bahn</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Bipolar</keyword>
  <keyword>atypical antipsychotics</keyword>
  <keyword>quality of life</keyword>
  <keyword>observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

